Clinical trials: Food Labeling
Healthy
A Food-Effect Study of BPI-16350 in Healthy Subjects
This study is intended to quantify the effect of food on the pharmacokinetics of BPI-16350. Subjects will be randomized to a crossover sequence at a 1:1 ratio and administered the dose of BPI-16350 on Day 1 in Period 1 and on Day…
- Trial name
- NCT05316259
- Testing
- BPI-16350
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Acne
ABSORICA in Patients With Severe Recalcitrant Nodular Acne
This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.
- Trial name
- NCT02457520
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Solid Tumor
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
This is a Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects with advanced solid tumors.
- Trial name
- NCT06143007
- Testing
- BB3008 tablet
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Broadenbio Ltd., Co.
Healthy
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants
The purpose of this study is to determine pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and the relative-bioavailability (the extent to which a drug or other substance becomes…
- Trial name
- NCT02260700
- Testing
- JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C)
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants
The main goal of this trial is to learn how a new tablet formulation of Lu AG06466 behaves in the body. Researchers will compare the new tablet formulation to the capsule formulation that is currently being tested in other…
- Trial name
- NCT05028673
- Testing
- Lu AG06466 Capsule, Lu AG06466 Tablet, Antacid
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy Participants
A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants
The purpose of the study is to estimate the relative bioavailability of a new minzasolmin tablet formulation versus reference 'granules in capsule' formulation in healthy participants and to evaluate the effect of food with the…
- Trial name
- NCT06533475
- Testing
- Minzasolmin tablet formulation under fasting condition, Minzasolmin Granules in capsule under fasting condition, Minzasolmin tablet formulation under fed condition
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 10773 given in free combination…
- Trial name
- NCT01189201
- Testing
- BI 10773/linagliptin, BI 10773/linagliptin SID, BI 10773/linagliptin FDC
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heathy Volunteer
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects
Primary objective To evaluate food effect on the pharmacokinetics (PK) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition.
- Trial name
- NCT03882112
- Testing
- HIP1601 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult…
- Trial name
- NCT06006702
- Testing
- TYRA-300-B01
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tyra Biosciences, Inc
Obesity, Diabetes
Testing the Effects of Singapore's Front-of-Pack Healthier Choice Symbol Label With or Without a Physical Activity Equivalent Label
Poor diets are known risk factors for chronic diseases, and in recent years, food labelling has been increasingly sought-after as a cost-effective intervention to help stem the rising trend in chronic diseases.
- Conditions
- Obesity, Diabetes, Diet, Healthy
- Trial name
- NCT04172337
- Testing
- Healthier Choice Symbol, Physical Activity Equivalent label
- Where
- Singapore
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Duke-NUS Graduate Medical School
Food Effect in Healthy Volunteers
A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200
This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.
- Trial name
- NCT05160389
- Testing
- PBI-200
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences
Cow Milk Allergy
Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula
This is a single arm, open label, multicenter intervention trial to evaluate growth parameters, cow's milk related symptoms, gastrointestinal tolerance and safety in infants with cow's milk allergy receiving a hydrolyzed protein…
- Trial name
- STORY (NCT05618704)
- Testing
- Hydrolyzed protein infant formula
- Where
- Poland
- Volunteers
- 69 people
- Sponsor
- Nutricia Research
Food Preferences, Obesity
Vending Labeling Sales and Intercepts Study
The aim of this study is to compare the impact of 4 different types of front of package (FOP) food and beverage messages: 1) green labels on healthy foods, 2) red/yellow/green labels on less healthy/moderately healthy/healthy…
- Conditions
- Food Preferences, Obesity, Weight Gain
- Trial name
- NCT06260176
- Testing
- exposure to healthy labels only, exposure to healthiness information, exposure to physical activity equivalents
- Where
- United States
- Volunteers
- 1,065 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cholecystitis
Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg
Primary objective of the study: evaluation of the effect of food intake on the bioavailability of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) after a single oral administration on an empty stomach and after a meal, at a dose of…
- Trial name
- NCT06342804
- Testing
- 4-MUST, 2 tablets, fasted, 4-MUST, 2 tablets, after meals
- Where
- Russia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Healthy Volunteer
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
This two-group study will investigate the effect of food (Group 1) and esomeprazole (Group 2) on the single oral dose pharmacokinetics of alectinib in healthy volunteers.
- Trial name
- NCT02023125
- Testing
- Alectinib, Esomeprazole, High Fat and Calorie Meal
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Peanut Allergy
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
- Trial name
- NCT03337542
- Testing
- AR101
- Where
- 60 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Aimmune Therapeutics, Inc.
IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
- Conditions
- IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy, IgE-Mediated Cow Milk Allergy
- Trial name
- NCT07408869
- Testing
- Cizutamig
- Where
- Australia
- Sponsor
- Candid Therapeutics
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
The primary objective of this trial is to investigate the safety and tolerability of BI 1358894 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03210272
- Testing
- BI 1358894, BI 1358894 (Test), BI 1358894 (Reference)
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim